Fang Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fang Luo has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Yang Zhao
State Key Laboratory of Organ Failure Research, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
5 shared publications Dingyao Chen
Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
3 shared publications- Kai Miao
Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau, China
3 shared publications Shaofang Ren
Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
3 shared publicationsWen Wang
Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
3 shared publicationsYi Zheng
Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
3 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by Springer Nature in Cell Regeneration
- Vol. 15 (1)
PRMT5 inhibition promotes cross-species spermatogonia expansion and suppresses differentiation
Spermatogonial stem cells (SSCs) hold great promise for treating male infertility, but their clinical translation is impeded by the lack of optimal conditions to maintain their undifferentiated state in vitro. In this study, we focused on epigenetic regulators upregulated during differentiation as potential targets. Through a small-molecule screen targeting such conserved regulators, we found that PRMT5 inhibition suppressed mouse SSC differentiation and enhanced their proliferation in a GDNF-deficient, differentiation-prone microenvironment in vitro. Using SSC transplantation assays, we confirmed that EPZ015666-treated SSCs retained their spermatogonial identity. This differentiation-inhibitory effect was reversible upon EPZ015666 withdrawal, allowing restoration of normal spermatogenesis. Notably, EPZ015666 also inhibited differentiation and promoted the proliferation of human and non-human primate spermatogonia in vitro. Mechanistically, EPZ015666 exerted this effect by inhibiting the enzymatic active site of PRMT5. These findings suggest that PRMT5 inhibition could provide a novel strategy for culturing human SSCs in vitro.
- 7 July 2026
- Published by Springer Nature in Cell Regeneration
- Vol. 15 (1)
Open AccessPRMT5 inhibition promotes cross-species spermatogonia expansion and suppresses differentiation
Spermatogonial stem cells (SSCs) hold great promise for treating male infertility, but their clinical translation is impeded by the lack of optimal conditions to maintain their undifferentiated state in vitro. In this study, we focused on epigenetic regulators upregulated during differentiation as potential targets. Through a small-molecule screen targeting such conserved regulators, we found that PRMT5 inhibition suppressed mouse SSC differentiation and enhanced their proliferation in a GDNF-deficient, differentiation-prone microenvironment in vitro. Using SSC transplantation assays, we confirmed that EPZ015666-treated SSCs retained their spermatogonial identity. This differentiation-inhibitory effect was reversible upon EPZ015666 withdrawal, allowing restoration of normal spermatogenesis. Notably, EPZ015666 also inhibited differentiation and promoted the proliferation of human and non-human primate spermatogonia in vitro. Mechanistically, EPZ015666 exerted this effect by inhibiting the enzymatic active site of PRMT5. These findings suggest that PRMT5 inhibition could provide a novel strategy for culturing human SSCs in vitro.
- Open Access
- 30 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Reconstitution of spermatogenesis and continuous generation of functional haploid germ cells in mouse testicular organoids
Testicular organoids that support spermatogenesis and generate functional haploid germ cells are still lacking. Here, we developed a formation-differentiation culture approach to generate optimized testicular organoids (O-Torgs) derived from neonatal mouse primary testicular cells. These O-Torgs could essentially recapitulate the seminiferous tubule morphogenesis, Sertoli cell maturation, and testosterone secretion. Importantly, O-Torgs not only support spermatogenesis but also sustain proliferative undifferentiated spermatogonia and continuous generation of functional haploid cells for up to three months, with offspring derived from these haploid cells displaying normal growth and reproductive capability to the F2 generation. Mechanistically, we found that the formation stage enhanced the reconstruction of tubule-like structures and subsequent spermatogenesis by providing a more conducive extracellular matrix niche. Finally, O-Torgs were proven to be effective in modeling male infertility and drug screening, with BTT-3033 acting as a potential drug in protecting busulfan-mediated germ cell loss. Overall, our work establishes a strategy to obtain functional testicular organoids, offering promising avenues for male infertility modeling and drug discovery.
- 30 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessReconstitution of spermatogenesis and continuous generation of functional haploid germ cells in mouse testicular organoids
Testicular organoids that support spermatogenesis and generate functional haploid germ cells are still lacking. Here, we developed a formation-differentiation culture approach to generate optimized testicular organoids (O-Torgs) derived from neonatal mouse primary testicular cells. These O-Torgs could essentially recapitulate the seminiferous tubule morphogenesis, Sertoli cell maturation, and testosterone secretion. Importantly, O-Torgs not only support spermatogenesis but also sustain proliferative undifferentiated spermatogonia and continuous generation of functional haploid cells for up to three months, with offspring derived from these haploid cells displaying normal growth and reproductive capability to the F2 generation. Mechanistically, we found that the formation stage enhanced the reconstruction of tubule-like structures and subsequent spermatogenesis by providing a more conducive extracellular matrix niche. Finally, O-Torgs were proven to be effective in modeling male infertility and drug screening, with BTT-3033 acting as a potential drug in protecting busulfan-mediated germ cell loss. Overall, our work establishes a strategy to obtain functional testicular organoids, offering promising avenues for male infertility modeling and drug discovery.
- Open Access
- 6 November 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-16
Atorvastatin improves spermatogenesis in murine and in vitro human chronic orchitis models through restoring blood-testis barriers
Chronic orchitis, which stems from autoimmune responses and infections, significantly impairs the testicular niche and affects male fertility. However, there is a lack of effective therapeutic drugs. In this study, we aimed to explore whether atorvastatin can be used for the treatment of chronic orchitis and the underlying mechanism based on our previous findings and detection using the database. We utilized mouse models of chronic orchitis induced by both autoimmune and infectious causes to demonstrate that atorvastatin can markedly improve spermatogenesis and fertility. Mechanism studies through single-cell transcriptomic analysis, target gene knockdown, quantitative proteomics, and small molecule interference revealed that atorvastatin suppressed the Rac1/AP1/MMPs pathway via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) in Sertoli cells, thereby restoring the blood-testis barrier (BTB) and spermatogenesis. More importantly, atorvastatin also re-established the expression of BTB-associated proteins and increased the germ cell numbers in cultured human testis tissues. Collectively, our study reveals the essential impact of atorvastatin in improving spermatogenesis in murine and human chronic orchitis models through restoring BTB and suggests that atorvastatin as a promising agent for the clinical treatment of chronic orchitis.
- 6 November 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-16
Open AccessAtorvastatin improves spermatogenesis in murine and in vitro human chronic orchitis models through restoring blood-testis barriers
Chronic orchitis, which stems from autoimmune responses and infections, significantly impairs the testicular niche and affects male fertility. However, there is a lack of effective therapeutic drugs. In this study, we aimed to explore whether atorvastatin can be used for the treatment of chronic orchitis and the underlying mechanism based on our previous findings and detection using the database. We utilized mouse models of chronic orchitis induced by both autoimmune and infectious causes to demonstrate that atorvastatin can markedly improve spermatogenesis and fertility. Mechanism studies through single-cell transcriptomic analysis, target gene knockdown, quantitative proteomics, and small molecule interference revealed that atorvastatin suppressed the Rac1/AP1/MMPs pathway via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) in Sertoli cells, thereby restoring the blood-testis barrier (BTB) and spermatogenesis. More importantly, atorvastatin also re-established the expression of BTB-associated proteins and increased the germ cell numbers in cultured human testis tissues. Collectively, our study reveals the essential impact of atorvastatin in improving spermatogenesis in murine and human chronic orchitis models through restoring BTB and suggests that atorvastatin as a promising agent for the clinical treatment of chronic orchitis.
- Open Access
- 8 May 2024
- Published by Wiley in FEBS Open Bio
- Vol. 14 (7) , 1087-1100
HELQ deficiency impairs the induction of primordial germ cell‐like cells
Helicase POLQ‐like (HELQ) is a DNA helicase essential for the maintenance of genome stability. A recent study identified two HELQ missense mutations in some cases of infertile men. However, the functions of HELQ in the process of germline specification are not well known and whether its function is conserved between mouse and human remains unclear. Here, we revealed that Helq knockout (Helq−/−) could significantly reduce the efficiency of mouse primordial germ cell‐like cell (PGCLC) induction. In addition, Helq−/− embryonic bodies exhibited a severe apoptotic phenotype on day 6 of mouse PGCLC induction. p53 inhibitor treatment could partially rescue the generation of mouse PGCLCs from Helq mutant mouse embryonic stem cells. Finally, the genetic ablation of HELQ could also significantly impede the induction of human PGCLCs. Collectively, our study sheds light on the involvement of HELQ in the induction of both mouse and human PGCLCs, providing new insights into the mechanisms underlying germline differentiation and the genetic studies of human fertility.
- 8 May 2024
- Published by Wiley in FEBS Open Bio
- Vol. 14 (7) , 1087-1100
Open AccessHELQ deficiency impairs the induction of primordial germ cell‐like cells
Helicase POLQ‐like (HELQ) is a DNA helicase essential for the maintenance of genome stability. A recent study identified two HELQ missense mutations in some cases of infertile men. However, the functions of HELQ in the process of germline specification are not well known and whether its function is conserved between mouse and human remains unclear. Here, we revealed that Helq knockout (Helq−/−) could significantly reduce the efficiency of mouse primordial germ cell‐like cell (PGCLC) induction. In addition, Helq−/− embryonic bodies exhibited a severe apoptotic phenotype on day 6 of mouse PGCLC induction. p53 inhibitor treatment could partially rescue the generation of mouse PGCLCs from Helq mutant mouse embryonic stem cells. Finally, the genetic ablation of HELQ could also significantly impede the induction of human PGCLCs. Collectively, our study sheds light on the involvement of HELQ in the induction of both mouse and human PGCLCs, providing new insights into the mechanisms underlying germline differentiation and the genetic studies of human fertility.
- Open Access
- 11 April 2023
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (4) , 969-984
Lovastatin promotes the self-renewal of murine and primate spermatogonial stem cells
- 11 April 2023
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (4) , 969-984
Open AccessLovastatin promotes the self-renewal of murine and primate spermatogonial stem cells